Latest issue of Clinical laboratory
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Lunaphore appoints Matthias Weber, former President of Leica Biosystems, to Board of Directors
, /in E-News /by panglobalLunaphore Technologies, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, has appointed Matthias Weber, former President of Leica Biosystems, to its Board of Directors. Weber has been appointed to represent the interests of strategic investor PHC Holdings Corporation (PHCHD), who previously invested in Lunaphore through a Series C financing round in 2020.
Bio-Rad launches SEQuoia RiboDepletion Kit for next-gen sequencing
, /in Product News /by Bio-Rad LaboratoriesBio-Rad Laboratories recently launched the SEQuoia RiboDepletion Kit, which improves assay efficiency by eliminating irrelevant ribosomal RNA (rRNA) fragments from an RNA-Seq library.
Iksuda Therapeutics closes $47 million financing round
, /in E-News /by panglobalIksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, has completed a US$47 million financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform […]
Aptamer Group, PinotBio collaborate to develop Optimer-drug conjugates
, /in E-News /by panglobalAptamer Group, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, have entered into a strategic collaboration agreement. The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
Beyondis reports positive results from Phase III trial of antibody-drug conjugate for breast cancer
, /in E-News /by panglobalByondis has reported positive topline results from the Phase III TULIP study, a multi-centre, open-label, randomized clinical trial. The trial compared the efficacy and safety of the company’s antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) to physician’s choice treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer.
Study shows Nova POC Creatinine/eGFR method more accurate PRODUCT than laboratory method
, /in Product News /by panglobalIn a 670-patient study funded by the International Society of Nephrology, the South Africa Medical Research Council, and the University of Witwatersrand, Johannesburg, South Africa, the Nova POC StatSensor Creatinine/eGFR meter was more accurate than the central laboratory IDMS-traceable Jaffe methodology in estimating GFR when both methods were compared to measured GFR (mGFR).
Celemics partners with Strand Life Science to develop bioinformatics solutions
, /in E-News /by panglobalCelemics has partnered with Strand Life Sciences to develop a bioinformatics solution capable of providing users with an accelerated means of producing high-quality, in-class clinical genomics reports and enabling a complete sample-to-answer solution, including assayspecific variant filters.
Algorics acquires Domain Clinical Data Sciences
, /in E-News /by panglobalAlgorics, a provider of biostatistics and programming solutions for the pharmaceutical and biotechnology industry, has acquired Domain Clinical Data Sciences (DCDS), a clinical data services organisation based in India.
AMSBIO releases Adeno-Associated Virus reference materials
, /in Product News /by panglobalAMSBIO has unveiled a new range of AAV reference materials of full capsids and empty capsids of six different serotypes.
Investors inject €2 million into Abviris to boost HPV cancer biomarker expansion
, /in E-News /by panglobalAbviris Deutschland, a biotech company, has received an injection of €2 million from existing investors to speed up expansion. The move comes after the publication of highly promising results for its pioneering immunoassay biomarker as an aid in the early diagnosis of head, neck and anogenital cancers caused by human papilloma viruses (HPV).